![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Friday, November 09, 2012 8:01:09 PM
CDXS Codexis handily beats Street consensus in Q3 earnings /consensus of (0.18),Actual (0.06)
Codexis handily beats Street consensus in Q3 earnings
Jim Lane | November 9, 2012
In California, Codexis, reported revenues for the third quarter of 2012 of $26.3 million, a 21% decrease from $33.3 million in the third quarter of 2011. Product revenue in the third quarter of 2012 was $7.1 million, a 41% decrease from $12.2 million in the prior year quarter and a 5% sequential increase from $6.8 million in the second quarter of 2012. the third quarter ended September 30, 2012. Net loss was $2.3 million, or a loss of $0.06 per share, based on 37.1 million weighted average common shares outstanding in the third quarter of 2012. This compares to a net loss of $2.7 million, or a loss of $0.08 per share during the third quarter of 2011.
Raymond James energy analyst Pavel Molchanov wrote: ” The net loss of $(0.06) per share was much better than our estimate of $(0.19) and consensus of $(0.18). Following its (amicable) divorce from Shell, Codexis is in a transitional period as it aims to reposition itself in the fuels and chemicals arena, in addition to growing its base pharma business. Balancing Codexis’ opportunity to be an early mover in cellulosic biofuels with the decidedly hazy commercialization timeline, we maintain our Market Perform rating.
“The 1,500-liter demonstration facility in Italy with partner Chemtex is progressing on track for a mid-2013 startup,” Molchanov added. “Codexis continues to work on its strain, with a particular focus on boosting yield. {Meanwhile} activity is progressing slowly with Raizen, which has yet to give clear targets for Gen2 biofuel scale-up. As we’ve mentioned before, supermajors like Shell invariably move slowly on new technologies, and that is holding true with the Raizen JV.
“As promised, Codexis went about the hard, but crucial work this quarter of strategically realigning the company for its forward growth strategy following the loss of Shell funding,” said John Nicols, President and CEO of Codexis. “In parallel, we are encouraged by solid developments in our pharma business having recently finalized a new, more profitable business arrangement with our manufacturing partner, Arch Pharmalabs. We are also developing early prospects for commercialization partners for our CodeXyme™ cellulase enzymes, which produce cellulosic sugars,” Nicols added.
http://www.biofuelsdigest.com/bdigest/2012/11/09/codexis-handily-beats-street-consensus-in-q3-earnings/
Recent ALTO News
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/08/2024 08:15:43 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/06/2024 08:13:30 PM
- Alto Ingredients, Inc. Reports First Quarter 2024 Results • GlobeNewswire Inc. • 05/06/2024 08:05:21 PM
- Alto Ingredients, Inc. to Release First Quarter 2024 Financial Results on May 6, 2024 • GlobeNewswire Inc. • 04/29/2024 12:30:15 PM
- Alto Ingredients, Inc. Appoints Todd E. Benton as Chief Operating Officer; Michael D. Kandris to Continue to Serve as Director • GlobeNewswire Inc. • 03/21/2024 12:30:49 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/11/2024 08:18:04 PM
- Alto Ingredients, Inc. Reports Fourth Quarter and Year-end 2023 Results • GlobeNewswire Inc. • 03/11/2024 08:05:08 PM
- Alto Ingredients, Inc. Enters Letter of Intent with Vault to Advance Carbon Capture and Storage Initiative • GlobeNewswire Inc. • 03/11/2024 08:02:21 PM
- Alto Ingredients, Inc. to Participate in the 36th Annual Roth Conference • GlobeNewswire Inc. • 03/05/2024 01:30:06 PM
- Alto Ingredients, Inc. to Release Fourth Quarter 2023 Financial Results • GlobeNewswire Inc. • 03/04/2024 01:30:24 PM
- Alto Ingredients, Inc. Publishes Sustainability Summary • GlobeNewswire Inc. • 12/11/2023 01:30:04 PM
- Alto Ingredients, Inc. Extends Term Loan Commitment Period • GlobeNewswire Inc. • 12/06/2023 01:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/08/2023 09:32:32 PM
- Alto Ingredients, Inc. to Participate in Upcoming Conferences • GlobeNewswire Inc. • 11/08/2023 01:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/06/2023 09:19:10 PM
- Alto Ingredients, Inc. Reports Third Quarter 2023 Results • GlobeNewswire Inc. • 11/06/2023 09:05:29 PM
- Alto Ingredients, Inc. to Release Third Quarter 2023 Financial Results • GlobeNewswire Inc. • 10/30/2023 12:30:00 PM
- Alto Ingredients, Inc. to Present at the LD Micro Main Event XVI • GlobeNewswire Inc. • 09/27/2023 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/20/2023 09:20:11 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/19/2023 08:05:34 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/19/2023 08:05:28 PM
- Alto Ingredients, Inc. to Present at the H.C. Wainwright & Co. 25th Annual Global Investment Conference • GlobeNewswire Inc. • 09/05/2023 12:30:03 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 08/09/2023 08:10:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/08/2023 08:16:45 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/07/2023 08:15:54 PM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM